Millennium Pharmaceuticals, Inc. (MLNM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	7/28/2006 4:08:31 PM
	of 3044

Millennium Pharmaceuticals "neutral," target price raised Friday, July 28, 2006 3:55:58 AM ET Robert W. Baird NEW YORK, July 28 (newratings.com) - Analysts at Robert W Baird reiterate their "neutral" rating on Millennium Pharmaceuticals Inc (MLNM.NAS), while raising their estimates for the company. The target price has been raised from $10 to $11. In a research note published this morning, the analysts mention the company has reported its non-GAAP EPS for the previous quarter ahead of the estimates and the consensus due to robust Velcade sales and efficient cost management. The analysts consider the company's Velcade sales guidance for FY06 as achievable, in view of the price hike with effect from July 1 and weaker-than-expected competition from Revlimid. The EPS estimates for 2006 and 2007 have been raised from $0.04 to $0.07 and from $0.15 to $0.17, respectively.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next